These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36318222)

  • 1. Clinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or Commitments.
    Kim J; Kester R; Blumenthal G
    Oncologist; 2022 Dec; 27(12):993-997. PubMed ID: 36318222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evaluation of Novel Oncology Approvals with a PMR/C for Assessing Data in Racial and Ethnic Populations Underrepresented in Premarket Clinical Trials.
    Collins G; Andrews HS; McKelvey B; Rice C; Allen JD; Stewart MD
    Clin Cancer Res; 2024 Aug; 30(16):3388-3394. PubMed ID: 38884580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minority Enrollment to Clinical Trials: Road to Increased Access.
    Vose J
    Oncology (Williston Park); 2021 Mar; 35(3):107. PubMed ID: 33818053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China.
    Ge C; An J; Chen X
    Heliyon; 2024 Aug; 10(15):e35454. PubMed ID: 39170111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA Initiative to Assure Racial and Ethnic Diversity in Clinical Trials.
    Adashi EY; Cohen IG
    J Am Board Fam Med; 2023 Apr; 36(2):366-368. PubMed ID: 36801846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
    Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
    Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies.
    Miller J; Pelletiers W; Suttiratana S; Mensah MO; Schwartz J; Ramachandran R; Gross C; Ross JS
    BMJ Med; 2024; 3(1):e000920. PubMed ID: 39175919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.
    Aldrighetti CM; Niemierko A; Van Allen E; Willers H; Kamran SC
    JAMA Netw Open; 2021 Nov; 4(11):e2133205. PubMed ID: 34748007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials.
    Mattei LH; Robb L; Banning K; Polan RM; Cote ML
    Obstet Gynecol; 2022 Oct; 140(4):654-661. PubMed ID: 36075065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory landscape with U.S. patient requirements and Clinical Trial Diversity expectations.
    George E; Baker McDowell A; Vozza M; Mitchell T; Quartley B; Kennedy CS; Hanlon B
    Contemp Clin Trials Commun; 2024 Dec; 42():101331. PubMed ID: 39314996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity Plans and Postmarketing Studies: First Impressions of Anticipated Diversity Requirements in the United States.
    Schouest B; Bindal KR
    Ther Innov Regul Sci; 2024 Jul; 58(4):704-713. PubMed ID: 38568346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
    Berkowitz ST; Groth SL; Gangaputra S; Patel S
    JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
    Allison K; Patel DG; Greene L
    JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement.
    Oyer RA; Hurley P; Boehmer L; Bruinooge SS; Levit K; Barrett N; Benson A; Bernick LA; Byatt L; Charlot M; Crews J; DeLeon K; Fashoyin-Aje L; Garrett-Mayer E; Gralow JR; Green S; Guerra CE; Hamroun L; Hardy CM; Hempstead B; Jeames S; Mann M; Matin K; McCaskill-Stevens W; Merrill J; Nowakowski GS; Patel MI; Pressman A; Ramirez AG; Segura J; Segarra-Vasquez B; Hanley Williams J; Williams JE; Winkfield KM; Yang ES; Zwicker V; Pierce LJ
    J Clin Oncol; 2022 Jul; 40(19):2163-2171. PubMed ID: 35588469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Drug Formulary Management and Utilization: Evidence in Sex, Race, and Ethnicity: 2019-2020.
    Keeys CA; Harding BW; Migneco GE; Rahini SS; Coleman HB
    Ann Pharmacother; 2022 Feb; 56(2):139-145. PubMed ID: 34049437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
    Merenda C
    J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.